Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12577001 | 0.84 | MAPT (0.41) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL455946 | 0.81 | KMT2A (0.47) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL458467 | 0.76 | HTR6 (0.43) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL29507322 | 0.74 | KMT2A (0.42) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL15489065 | 0.72 | KMT2A (0.41) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL22915921 | 0.69 | GLA (0.41) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL29507323 | 0.69 | MAPT (0.44) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL22915923 | 0.69 | GLA (0.40) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL22915922 | 0.67 | KLK7 (0.43) | MAPTHTTSMN1; SMN2LMNAGAA | |
| SCHEMBL459666 | 0.66 | SMN1; SMN2 (0.39) | MAPTHTTSMN1; SMN2LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9326987-B2 | Indazole derivatives for use in the treatment of influenza virus infection | GLAXO GROUP LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| US-8658635-B2 | Benzpyrazol derivatives as inhibitors of PI3 kinases | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| EP-2300437-B1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| EP-2613781-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165433-A1 | Novel Use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2013-06-27 | — | — | US | disclosed |
| EP-2507223-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| EP-2507226-A1 | NOVEL COMPOUNDS | Glaxo Group Limited (GB) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2012-09-27 | — | — | US | disclosed |
| US-20120238559-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-09-20 | — | — | US | disclosed |
| WO-2012032065-A1 | INDAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF INFLUENZA VIRUS INFECTION | GLAXO GROUP LIMITED (GB) | 2012-03-15 | — | — | WO | disclosed |
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | US | disclosed |
| WO-2011067364-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067365-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF P13 KINASES | GLAXO GROUP LIMITED (GB) | 2011-06-09 | — | — | WO | disclosed |
| EP-2300437-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | Glaxo Group Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009147188-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | GLAXO GROUP LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178063-A1 | BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3CA, PIK3CD, PI4KA | MAPT 2759/4885HTT 4069/4885SMN1; SMN2 3935/4885 |
| US-20130165433-A1 | Novel Use | HAVCR2, MAVS, ENTPD5 | MAPT 3121/4885HTT 3804/4885SMN1; SMN2 4600/4885 |
| US-20120238559-A1 | NOVEL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | MAPT 2143/4885HTT 3122/4885SMN1; SMN2 4190/4885 |
| US-20120245171-A1 | BENZPYRAZOLE DERIVATIVES AS INHIBITORS OF PI3 KINASES | PIK3C3, PIK3CA, PIK3CD | MAPT 2733/4885HTT 3814/4885SMN1; SMN2 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.